

# NEUROENDOCRINE TUMOR STAGING FORM

CLINICAL <i>Extent of disease before any treatment</i>	STAGE CATEGORY DEFINITIONS	PATHOLOGIC <i>Extent of disease through completion of definitive surgery</i>
<input type="checkbox"/> y clinical – staging completed after neoadjuvant therapy but before subsequent surgery	<b>TUMOR SIZE:</b> _____	<input type="checkbox"/> y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery
<input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4	<p style="text-align: center;"><b>PRIMARY TUMOR (T)</b></p> <p><b>Stomach</b>            Primary tumor cannot be assessed            No evidence of primary tumor            Carcinoma <i>in situ</i>/dysplasia (tumor size &lt;0.5mm), confined to mucosa            Tumor invades lamina propria or submucosa and ≤1cm in size            Tumor invades muscularis propria or &gt;1cm in size            Tumor penetrates subserosa            Tumor invades visceral peritoneum (serosa) or other organs or adjacent structures            For any T, add (m) for multiple tumors</p> <p><b>Duodenum/Ampulla/Jejunum/Ileum</b>            Primary tumor cannot be assessed            No evidence of primary tumor            Tumor invades lamina propria or submucosa and size ≤1 cm (small intestinal tumors); tumor ≤1 cm (ampullary tumors)            Tumor invades muscularis propria or size &gt;1 cm (small intestinal tumors); tumor &gt;1 cm (ampullary tumors)            Tumor invades through the muscularis propria into subserosal tissue without penetration of overlying serosa (jejunal or ileal tumors) or invades pancreas or retroperitoneum (ampullary or duodenal tumors) or into non-peritonealized tissues.            Tumor invades visceral peritoneum (serosa) or invades other organs            For any T, add (m) for multiple tumors            *Tumor limited to ampulla of Vater for ampullary gangliocytic paraganglioma</p> <p><b>Colon or Rectum</b>            Primary tumor cannot be assessed            No evidence of primary tumor            Tumor invades lamina propria or submucosa and size ≤2 cm            Tumor size &lt;1 cm in greatest dimension            Tumor size 1 to 2 cm in greatest dimension            Tumor invades muscularis propria or size &gt;2 cm with invasion of lamina propria or submucosa            Tumor invades through the muscularis propria into the subserosa, or into non-peritonealized pericolic or perirectal tissues            Tumor invades peritoneum or other organs            For any T, add (m) for multiple tumors</p>	<input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4  <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> T1  <input type="checkbox"/> T2 <input type="checkbox"/> T3  <input type="checkbox"/> T4  <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> T1 <input type="checkbox"/> T1a <input type="checkbox"/> T1b <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4
<input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1	<p style="text-align: center;"><b>REGIONAL LYMPH NODES (N)</b></p> <p><b>Stomach</b>            Regional lymph nodes cannot be assessed            No regional lymph node metastasis            Regional lymph node metastasis</p>	<input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1

<b>HOSPITAL NAME/ADDRESS</b>	<b>PATIENT NAME/INFORMATION</b>
------------------------------	---------------------------------

*(continued on next page)*

## NEUROENDOCRINE TUMOR STAGING FORM

<input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1  <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1	<p><b>Duodenum/Ampulla/Jejunum/Ileum</b>          Regional lymph nodes cannot be assessed          No regional lymph node metastasis          Regional lymph node metastasis</p> <p><b>Colon or Rectum</b>          Regional lymph nodes cannot be assessed          No regional lymph node metastasis          Regional lymph node metastasis</p>	<input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1  <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1
<b>DISTANT METASTASIS (M)</b>		
<input type="checkbox"/> M0 <input type="checkbox"/> M1  <input type="checkbox"/> M0 <input type="checkbox"/> M1  <input type="checkbox"/> M0 <input type="checkbox"/> M1	<p><b>Stomach</b>          No distant metastasis (no pathologic M0; use clinical M to complete stage group)          Distant metastasis</p> <p><b>Duodenum/Ampulla/Jejunum/Ileum</b>          No distant metastasis (no pathologic M0; use clinical M to complete stage group)          Distant metastasis</p> <p><b>Colon or Rectum</b>          No distant metastasis (no pathologic M0; use clinical M to complete stage group)          Distant metastasis</p>	<input type="checkbox"/> M1   <input type="checkbox"/> M1   <input type="checkbox"/> M1

### ANATOMIC STAGE • PROGNOSTIC GROUPS

CLINICAL					PATHOLOGIC				
GROUP	T	N	M		GROUP	T	N	M	
<input type="checkbox"/> 0	Tis*	N0	M0		<input type="checkbox"/> 0	Tis*	N0	M0	
<input type="checkbox"/> I	T1	N0	M0		<input type="checkbox"/> I	T1	N0	M0	
<input type="checkbox"/> IIA	T2	N0	M0		<input type="checkbox"/> IIA	T2	N0	M0	
<input type="checkbox"/> IIB	T3	N0	M0		<input type="checkbox"/> IIB	T3	N0	M0	
<input type="checkbox"/> IIIA	T4	N0	M0		<input type="checkbox"/> IIIA	T4	N0	M0	
<input type="checkbox"/> IIIB	Any T	N1	M0		<input type="checkbox"/> IIIB	Any T	N1	M0	
<input type="checkbox"/> IV	Any T	Any N	M1		<input type="checkbox"/> IV	Any T	Any N	M1	
<input type="checkbox"/> Stage unknown					<input type="checkbox"/> Stage unknown				
*Note: Tis applies only to stomach.					*Note: Tis applies only to stomach.				

PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)	General Notes:								
<p><b>REQUIRED FOR STAGING:</b> None</p> <p><b>CLINICALLY SIGNIFICANT:</b>            Pre-operative plasma chromogranin A level (CgA) _____            Urinary 5-hydroxyindolacetic acid (5-HIAA) level _____            Mitotic count _____</p> <p><b>Histologic Grade (G)</b> (also known as overall grade)</p> <table style="width: 100%;"> <tr> <th style="text-align: left;">Grading system</th> <th style="text-align: left;">Grade</th> </tr> <tr> <td><input type="checkbox"/> 2 grade system</td> <td><input type="checkbox"/> Grade I or 1</td> </tr> <tr> <td><input type="checkbox"/> 3 grade system</td> <td><input type="checkbox"/> Grade II or 2</td> </tr> <tr> <td><input type="checkbox"/> No 2 or 3 grade system is available</td> <td><input type="checkbox"/> Grade III or 3</td> </tr> </table>	Grading system	Grade	<input type="checkbox"/> 2 grade system	<input type="checkbox"/> Grade I or 1	<input type="checkbox"/> 3 grade system	<input type="checkbox"/> Grade II or 2	<input type="checkbox"/> No 2 or 3 grade system is available	<input type="checkbox"/> Grade III or 3	<p>For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.</p> <p><b>m suffix</b> indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.</p> <p><b>y prefix</b> indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix.</p>
Grading system	Grade								
<input type="checkbox"/> 2 grade system	<input type="checkbox"/> Grade I or 1								
<input type="checkbox"/> 3 grade system	<input type="checkbox"/> Grade II or 2								
<input type="checkbox"/> No 2 or 3 grade system is available	<input type="checkbox"/> Grade III or 3								

<b>HOSPITAL NAME/ADDRESS</b>	<b>PATIENT NAME/INFORMATION</b>
------------------------------	---------------------------------

*(continued from previous page)*

## NEUROENDOCRINE TUMOR STAGING FORM

**ADDITIONAL DESCRIPTORS**

**Lymphatic Vessel Invasion (L) and Venous Invasion (V)** have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- Lymph-Vascular Invasion Not Present (absent)/Not Identified
- Lymph-Vascular Invasion Present/Identified
- Not Applicable
- Unknown/Indeterminate

**Residual Tumor (R)**

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

**General Notes (continued):**

The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.

**r prefix** indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.

**a prefix** designates the stage determined at autopsy: aTNM.

**surgical margins** is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

**neoadjuvant treatment** is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

Clinical stage was used in treatment planning (describe): \_\_\_\_\_

National guidelines were used in treatment planning     NCCN     Other (describe): \_\_\_\_\_

Physician signature

Date/Time

<p><b>HOSPITAL NAME/ADDRESS</b></p>	<p><b>PATIENT NAME/INFORMATION</b></p>
-------------------------------------	--